Lauri-Jo Gamble1, Jordyn M. Boesch1, Christopher W. Frye1, Wayne S. Schwark2, Sabine Mann3, Lisa Wolfe4, Holly Brown5, Erin S. Berthelsen1 and Joseph J. Wakshlag1*
1 Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY, United States, 2 Department of Molecular medicine, College of Veterinary Medicine, Cornell University, Ithica, NY, United States, 3 Department of Population Medicine, College of veterinary Medicine, Cornell Univeristy, Ithaca, NY, United States, 4 Proteomic and Metabolomic Facility, Colorado State University, Fort Collins, CO, United States, 5 Metzger Animal Hospital, State College, PA, United States
Pharmacokinetics revealed an elimination half-life of 4.2h at both doses and no observable side effects. Clinically, canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity (p < 0.01) with CBD oil. Veterinary assessment showed decreased pain during CBD treatment (p < 0.02). No side effects were reported by owners, however, serum chemistry showed an increase in alkaline phosphatase during CBD treatment (p < 0.01).